Your browser is no longer supported. Please, upgrade your browser.
Marinus Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.05 Insider Own0.10% Shs Outstand27.27M Perf Week-1.74%
Market Cap505.15M Forward P/E- EPS next Y-2.32 Insider Trans-55.55% Shs Float24.71M Perf Month-8.83%
Income-76.40M PEG- EPS next Q-0.45 Inst Own87.50% Short Float18.05% Perf Quarter-2.41%
Sales1.70M P/S297.15 EPS this Y29.50% Inst Trans0.19% Short Ratio15.58 Perf Half Y4.81%
Book/sh4.87 P/B2.91 EPS next Y-19.00% ROA-68.20% Target Price- Perf Year78.66%
Cash/sh3.92 P/C3.61 EPS next 5Y20.00% ROE-88.00% 52W Range6.04 - 20.04 Perf YTD15.98%
Dividend- P/FCF- EPS past 5Y15.90% ROI-51.20% 52W High-29.39% Beta1.42
Dividend %- Quick Ratio13.60 Sales past 5Y- Gross Margin- 52W Low134.27% ATR0.70
Employees65 Current Ratio13.60 Sales Q/Q- Oper. Margin- RSI (14)45.46 Volatility3.81% 5.02%
OptionableYes Debt/Eq0.00 EPS Q/Q37.10% Profit Margin- Rel Volume0.99 Prev Close14.09
ShortableYes LT Debt/Eq0.00 EarningsMay 13 AMC Payout- Avg Volume286.22K Price14.15
Recom1.50 SMA20-1.29% SMA50-7.21% SMA2009.89% Volume282,558 Change0.43%
Sep-30-20Initiated Truist Buy $35
Jul-01-20Reiterated H.C. Wainwright Buy $6 → $9
Jul-01-20Initiated Cowen Outperform
Apr-09-20Initiated Craig Hallum Buy $4.50
Dec-20-19Initiated Oppenheimer Outperform
Mar-05-19Resumed Jefferies Buy $3.50 → $10
Feb-27-19Downgrade Mizuho Buy → Neutral $13 → $5
Feb-06-19Initiated Leerink Partners Outperform $10
Jul-02-18Initiated Cantor Fitzgerald Overweight $19
Mar-20-18Initiated Mizuho Buy $13
Feb-15-18Initiated H.C. Wainwright Buy $33
Dec-14-17Initiated Laidlaw Buy $18
Aug-10-16Reiterated Jefferies Buy $2.50 → $3
Jun-14-16Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-08-16Reiterated Stifel Buy $23 → $16
Dec-17-15Initiated RBC Capital Mkts Outperform $14
Nov-17-15Initiated Jefferies Buy $14
Oct-30-15Reiterated Oppenheimer Outperform $21 → $17
Aug-05-15Reiterated Oppenheimer Outperform $12 → $21
May-07-21 07:57AM  
Apr-28-21 04:30PM  
Apr-16-21 05:50AM  
Apr-12-21 05:30PM  
Mar-24-21 09:00AM  
Mar-09-21 08:55AM  
Feb-23-21 07:00AM  
Feb-17-21 07:00AM  
Feb-15-21 01:57AM  
Feb-12-21 04:01PM  
Feb-10-21 07:31AM  
Jan-28-21 12:13PM  
Jan-26-21 07:01AM  
Jan-14-21 10:46AM  
Jan-13-21 07:01AM  
Jan-06-21 07:02AM  
Jan-04-21 09:27AM  
Dec-21-20 07:02AM  
Dec-14-20 11:39AM  
Dec-08-20 06:20PM  
Dec-07-20 04:01PM  
Dec-04-20 05:57PM  
Dec-02-20 07:02AM  
Nov-23-20 01:43PM  
Nov-15-20 09:34AM  
Nov-12-20 06:38AM  
Nov-10-20 04:01PM  
Nov-09-20 05:15PM  
Nov-02-20 01:22PM  
Oct-20-20 07:33AM  
Oct-19-20 04:07PM  
Oct-14-20 10:54PM  
Sep-25-20 07:37AM  
Sep-24-20 04:01PM  
Sep-22-20 09:14AM  
Sep-16-20 08:00AM  
Sep-15-20 07:09PM  
Sep-14-20 04:01PM  
Sep-08-20 04:01PM  
Aug-27-20 03:30PM  
Aug-25-20 08:52AM  
Aug-11-20 08:04PM  
Aug-06-20 07:30AM  
Aug-04-20 12:13PM  
Jul-30-20 10:52AM  
Jul-29-20 04:00PM  
Jul-08-20 09:19PM  
Jun-30-20 07:00AM  
Jun-24-20 08:00AM  
Jun-22-20 10:16AM  
Jun-17-20 08:44AM  
Jun-16-20 06:39PM  
Jun-15-20 07:30AM  
Jun-02-20 04:01PM  
May-28-20 09:23PM  
May-14-20 02:22PM  
May-09-20 07:51AM  
May-04-20 07:30AM  
May-03-20 08:45AM  
Apr-30-20 07:30AM  
Apr-27-20 04:01PM  
Apr-23-20 07:30AM  
Apr-14-20 09:28PM  
Mar-23-20 04:38PM  
Mar-20-20 10:21AM  
Mar-19-20 07:30AM  
Mar-18-20 08:19AM  
Mar-16-20 07:30AM  
Feb-25-20 07:30AM  
Feb-24-20 07:30AM  
Feb-14-20 04:05PM  
Feb-03-20 07:30AM  
Jan-20-20 04:37AM  
Jan-13-20 07:30AM  
Jan-07-20 07:30AM  
Dec-26-19 09:00AM  
Dec-24-19 11:29AM  
Dec-23-19 08:30AM  
Dec-13-19 04:44PM  
Dec-12-19 07:30AM  
Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, and postpartum depression. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VITULLO NICOLEDirectorMar 15Sale15.874,25067,4480Mar 16 04:58 PM
Smith Edward FFormer VP, CFO & TreasurerMar 09Option Exercise4.1635,927149,45653,644Mar 11 04:04 PM
Smith Edward FFormer VP, CFO & TreasurerMar 09Sale17.8040,356718,33713,288Mar 11 04:04 PM